Skip to Content

Smith & Nephew PLC

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 4,123.00YlmxmzzMhythpd

Smith & Nephew Seeks to Build on Its Strength in ASCs; Slight Cut to Our Fair Value Estimate

Business Strategy and Outlook

Impressive innovation has allowed Smith & Nephew to carve out a slice of the orthopedic, sports medicine, and wound-care markets. Though the company is smaller than the dominant orthopedic competitors, it has punched above its weight in terms of introducing meaningful innovation with its pioneering hip resurfacing implant and knee replacements with Verilast technology, which it contends can last for 30 years. These are significant improvements that exceed the evolutionary innovation typically seen in orthopedics.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SN. so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center